The EU vetoes the buyout of promising US cancer test startup Grail by biotech giant Illumina over fears the deal could one day create a monopoly. Illumina's takeover of fellow US company Grail would "stifle the ongoing innovation race between Grail and its rivals, and ultimately lead to less innovation, less choice and higher prices" says the European Commission. SOUNDBITE

Interested in licensing this video ? Get in touch 👉 http://u.afp.com/UBbQ
N.B.: AFP’s services and content are for professional use only